Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu
- 18 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 66 (1), 263-272
- https://doi.org/10.1007/s10620-020-06196-4
Abstract
Introduction The prevalence of coronary artery disease (CAD) is high among patients with cirrhosis; however, the impact of it on cardiovascular disease (CVD) is not known. The aim of the current study was to evaluate CVD events in patients with cirrhosis and impact of cirrhosis on biomarkers of atherogenesis. Methods The study included 682 patients with decompensated cirrhosis referred for liver transplantation (LT) evaluation between 2010 and 2017. All patients were followed until they experienced a CVD event, non-cardiac death, liver transplantation or last follow-up. To evaluate mechanistic link, patients with NASH cirrhosis were propensity matched 1:2 to non-cirrhosis NASH patients and biomarkers of atherogenic risk were compared. Results The composite CVD outcome occurred in 23(3.4%) patients after a median follow-up period of 585 days (IQR 139, 747). A strong association between presence of any CAD and CVD event was noted (HR = 6.8, 95% CI 2.9, 15.9) that was independent of age, gender, BMI, and MELD score. In competing risk model, the combined rate of LT and non-cardiac was significantly higher when compared to the rate of CVD events. Marker of insulin resistance and inflammation-related markers were similar in patients with and without cirrhosis. Patients with cirrhosis were more likely to have reduced VLDL, sdLDL-C, LDL-C, and triglycerides. Interestingly, patients with cirrhosis had an increase in serum HDL-2, the anti-atherogenic lipoprotein, and adiponectin, a protective serum adipokine. Conclusion The risk of CVD events in patients with cirrhosis is low and may potentially be due to improvement in markers of atherogenic risk.Keywords
This publication has 43 references indexed in Scilit:
- Homocysteine and Reclassification of Cardiovascular Disease RiskJournal of the American College of Cardiology, 2011
- Lipolysis – A highly regulated multi-enzyme complex mediates the catabolism of cellular fat storesProgress in Lipid Research, 2011
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010
- Screening Stress Myocardial Perfusion Imaging and Eligibility for Liver TransplantationThe American Journal of Cardiology, 2010
- Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjectsCardiovascular Diabetology, 2010
- C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart StudyCirculation: Cardiovascular Quality and Outcomes, 2008
- Apolipoprotein CIII and AtherosclerosisCirculation, 2008
- ACC/AHA/HRS 2006 Key Data Elements and Definitions for Electrophysiological Studies and ProceduresCirculation, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Low Plasma Adiponectin Levels Predict Progression of Coronary Artery CalcificationCirculation, 2005